Respiratory syncytial virus Clinical Trials

35 recruitingLast updated: July 25, 2026

There are 35 actively recruiting respiratory syncytial virus clinical trials across 24 countries. Studies span Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1, Phase 4. Top locations include Chengdu, Sichuan, China, Beijing, Beijing Municipality, China, Bangkok, Thailand. Updated daily from ClinicalTrials.gov.


Respiratory syncytial virus Trials at a Glance

35 actively recruiting trials for respiratory syncytial virus are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in Chengdu, Beijing, and Bangkok. Lead sponsors running respiratory syncytial virus studies include GlaxoSmithKline, Sanofi, and AstraZeneca.

Browse respiratory syncytial virus trials by phase

Treatments under study

About Respiratory syncytial virus Clinical Trials

Looking for clinical trials for Respiratory syncytial virus? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Respiratory syncytial virus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Respiratory syncytial virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Not Applicable

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Respiratory Syncytial Virus (RSV)
AstraZeneca138 enrolled6 locationsNCT06851806
Recruiting
Phase 2

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

RSV InfectionRespiratory Syncytial Virus (RSV)RSV
Enanta Pharmaceuticals, Inc150 enrolled8 locationsNCT07482657
Recruiting
Phase 1Phase 2

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

Respiratory Syncytial Virus Infections+Metapneumovirus
GlaxoSmithKline1,808 enrolled4 locationsNCT07628049
Recruiting
Phase 2

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Respiratory Syncytial Virus Infections
Shionogi192 enrolled80 locationsNCT07214571
Recruiting
Phase 3

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Respiratory Syncytial Virus Infections
Kexing Biopharm Co., Ltd.322 enrolled1 locationNCT06363370
Recruiting
Phase 2Phase 3

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

Respiratory Syncytial Virus Infections
Shanghai Ark Biopharmaceutical Co., Ltd.290 enrolled9 locationsNCT07658534
Recruiting
Phase 1Phase 2

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Systemic Inflammatory Response SyndromeSARS CoV-2Respiratory distress syndrome+2 more
PEACHES BIOTECH50 enrolled3 locationsNCT06684379
Recruiting
Phase 2

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Hematopoietic and Lymphatic System NeoplasmAutoimmune DiseaseRespiratory Syncytial Virus Infection
Fred Hutchinson Cancer Center60 enrolled3 locationsNCT06817889
Recruiting
Phase 1Phase 2

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.137 enrolled15 locationsNCT05655182
Recruiting
Phase 3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

Respiratory Syncytial Virus (RSV)
Pfizer130 enrolled5 locationsNCT07543380
Recruiting
Phase 3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Infections
GlaxoSmithKline750 enrolled15 locationsNCT07220109
Recruiting
Phase 1Phase 2

Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.

Respiratory Syncytial Virus Infections
Ab&B Bio-tech Co., Ltd.JS470 enrolled1 locationNCT07582796
Recruiting
Phase 1

Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age

Respiratory Syncytial Virus (RSV)Influenza A(H5N1)
Sanofi570 enrolled6 locationsNCT07516418
Recruiting
Phase 3

A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

Respiratory Syncytial Virus Infection
Simcere Pharmaceutical Co., Ltd498 enrolled4 locationsNCT07402512
Recruiting
Phase 2

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Respiratory Syncytial Virus Infections
GlaxoSmithKline184 enrolled37 locationsNCT07092865
Recruiting
Phase 3

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

Respiratory Syncytial Virus Infections
University of Alabama at Birmingham370 enrolled15 locationsNCT05026749
Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Streptococcus PneumoniaeMalariaMeningitis+55 more
Institut Pasteur du Cambodge10,000 enrolled1 locationNCT07358910
Recruiting

COVID-19 Impact on RSV Emergency Presentations

Bronchiolitis; Respiratory Syncytial Virus
University Hospitals, Leicester3,000 enrolled1 locationNCT04959734
Recruiting
Phase 2

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

Respiratory Syncytial Virus (RSV)
Johns Hopkins University170 enrolled1 locationNCT07050732
Recruiting
Phase 3

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

Respiratory Syncytial Virus (RSV)
MAXVAX Biotechnology Limited Liability Company25,000 enrolled8 locationsNCT07272434